Keytruda backed by NICE for late-stage oesophageal cancerMSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making Share XKeytruda backed by NICE for late-stage oesophageal cancerhttps://pharmaphorum.com/news/keytruda-backed-by-nice-for-late-stage-oesophageal-cancer/
Taking stock of NHS medicines optimisationGiven the rising cost of medicines as a share of the NHS budget in England, the establishment of Share XTaking stock of NHS medicines optimisationhttps://pharmaphorum.com/patients/nhs-confederation-medicines-optimisation-ics/
NHS England starts largest ever trial of Galleri cancer blood testA blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will Share XNHS England starts largest ever trial of Galleri cancer blood testhttps://pharmaphorum.com/news/nhs-england-starts-largest-ever-trial-of-galleri-cancer-blood-test/
NHS fast tracks access to Amgen’s just-approved KRAS cancer drugAmgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement Share XNHS fast tracks access to Amgen’s just-approved KRAS cancer drughttps://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/
AZ CEO Soriot urges caution on COVID booster dosesThe UK should think twice before backing widespread use of COVID-19 booster vaccinations, as to do so could Share XAZ CEO Soriot urges caution on COVID booster doseshttps://pharmaphorum.com/news/az-ceo-soriot-urges-caution-on-covid-booster-doses/
NICE changes its mind on J&J’s Erleada in prostate cancerNICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed Share XNICE changes its mind on J&J’s Erleada in prostate cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-jjs-erleada-in-prostate-cancer/
UK pledges £5.4bn to NHS to ease COVID-19 treatment backlogNHS England will get an extra £5.4 billion ($7.5 billion) in funding over the next six months to Share XUK pledges £5.4bn to NHS to ease COVID-19 treatment backloghttps://pharmaphorum.com/news/uk-pledges-5-4bn-to-nhs-to-ease-covid-19-treatment-backlog/
Study backs benefit of insomnia DTx Sleepio on mental healthA study has shown that people with anxiety or depression who used a digital therapeutic (DTx) for insomnia Share XStudy backs benefit of insomnia DTx Sleepio on mental healthhttps://pharmaphorum.com/news/study-backs-benefit-of-insomnia-dtx-sleepio-on-mental-health/
NICE backs Cosentyx’ use in thousands of children with psoriasisNICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17 Share XNICE backs Cosentyx’ use in thousands of children with psoriasishttps://pharmaphorum.com/news/nice-backs-cosentyx-use-in-thousands-of-children-with-psoriasis/
